Dr. Schinazi is Professor of Pediatrics and Chemistry and Director of the Laboratory of Biochemical Pharmacology at Emory University. He received his Ph.D. in Chemistry in 1976 from the University of Bath, England, and completed post-doctoral training in Pharmacology at Yale University and in Virology/Immunology at Emory University. He serves as the Senior Research Career Scientist at the Atlanta Department of Veterans Affairs and Director of the Pharmacology/Drug Discovery Core for the NIH-sponsored Emory University Center for AIDS Research (CFAR). Dr. Schinazi is the founder of several biotechnology companies focusing on antiviral drug discovery and development, including Pharmasset Inc., Triangle Pharmaceuticals (acquired by Gilead in 2003), Idenix Pharmaceuticals (51% acquired by Novartis in 2003), and RFS Pharma LLC (formed in Sept 2004). He is best known for his innovative and pioneering work on d4T (stavudine), 3TC (lamivudine), FTC (emtriva), D-D4FC (reverset), RCV (racivir), and DAPD (amdoxovir), drugs that are now approved by the FDA, or are at various stages of clinical development. His inventions now sell more than US$2.0 billion per year and more than 80% of the HIV infected individuals take at least one of the drugs he invented. Dr. Schinazi is on the editorial board of several journals, including Antimicrobial Agents and Chemotherapy, Antiviral Research, AIDS Reviews, Antiviral Chemistry and Chemotherapy and Antiviral Therapy. He is the founder of the highly successful HIV- and HEP-DART conferences. He also served on the Presidential Commission on AIDS. Dr. Schinazi brings his extensive experience in drug discovery and development to VIC.